| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Etie S Moghiss. Treating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combination. The Journal of the American Osteopathic Association. vol 114. issue 5 Suppl 2. 2015-08-18. PMID:24769505. |
incretin-based therapies, particularly glp-1 receptor agonists, provide postprandial control with lower risks of hypoglycemia than prandial insulin. |
2015-08-18 |
2023-08-13 |
Not clear |
| Francisco Javier Escalad. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus]. Medicina clinica. vol 143 Suppl 2. 2015-08-17. PMID:25437458. |
biological activities of glp-1 include stimulation of insulin biosynthesis and glucose-dependent insulin secretion by pancreatic beta cell, inhibition of glucagon secretion, delay of gastric emptying and inhibition of food intake. |
2015-08-17 |
2023-08-13 |
Not clear |
| Esteban Jóda. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy]. Medicina clinica. vol 143 Suppl 2. 2015-08-17. PMID:25437460. |
glucagon-like peptide 1 (glp-1) is secreted from enteroendocrine l-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. |
2015-08-17 |
2023-08-13 |
Not clear |
| Robert L Dobbins, Frank L Greenway, Lihong Chen, Yaping Liu, Sharon L Breed, Susan M Andrews, Jeffrey A Wald, Ann Walker, Chari D Smit. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. American journal of physiology. Gastrointestinal and liver physiology. vol 308. issue 11. 2015-08-12. PMID:25767259. |
sglt1 inhibitor effects on plasma glucose, insulin, gastric inhibitory peptide (gip), and glucagon-like peptide-1 (glp-1) concentrations were also measured during a standard meal. |
2015-08-12 |
2023-08-13 |
human |
| Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Hirohiko Sato, Kozo Yoshikawa, Tomohiko Miyatani, Chie Takasu, Noriko Matsumoto, Hiroki Ishibash. Duodenal-Jejunal Bypass Improves Insulin Resistance by Enhanced Glucagon-Like Peptide-1 Secretion Through Increase of Bile Acids. Hepato-gastroenterology. vol 61. issue 132. 2015-08-12. PMID:26158164. |
the aim of this study is to investigate the mechanisms of improvement in insulin resistance after duodenal-jejunal bypass (dib), especially regarding the correlation between bile acids and glucagon-like peptide-1 (glp-1). |
2015-08-12 |
2023-08-13 |
Not clear |
| Haitham Abdulla, Bethan Phillips, Kenneth Smith, Daniel Wilkinson, Philip J Atherton, Iskandar Idri. Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism. Current diabetes reviews. vol 10. issue 5. 2015-08-11. PMID:25323297. |
meanwhile glucagon-like peptide (glp-1) and glucose- dependent insulinotropic peptide (gip) are incretin hormones released from the gut into the bloodstream in response to macronutrients, and have an established role in enhancing insulin secretion. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
combining a glp-1 receptor agonist and basal insulin: study evidence and practical considerations. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
basal insulin and glucagon-like peptide 1 (glp-1) receptor agonists are frequently used to treat type 2 diabetes. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
basal insulin added to a glp-1 receptor agonist reduces hemoglobin a1c (hba1c) without weight gain or significantly increased hypoglycemia. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
a glp-1 receptor agonist added to basal insulin reduces hba1c and body weight. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
compared with the addition of meal-time insulin to basal insulin, a glp-1 receptor agonist produces similar or greater reduction in hba1c, weight loss instead of weight gain, and less hypoglycemia. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
however, combination with basal insulin is not expected to augment expected adverse events that come with using a glp-1 receptor agonist. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
basal insulin can be added to a glp-1 receptor agonist with a slow titration to target goal fasting plasma glucose. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
in patients starting a glp-1 receptor agonist, the dose of basal insulin should be decreased by 20 % in patients with an hba1c ≤8 %. |
2015-08-11 |
2023-08-13 |
Not clear |
| Nicholas W Carris, James R Taylor, John G Gum. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. vol 74. issue 18. 2015-08-11. PMID:25414121. |
the evidence from 15 randomized prospective studies supports the combined use of a glp-1 receptor agonist with basal insulin in a broad range of patients with uncontrolled type 2 diabetes. |
2015-08-11 |
2023-08-13 |
Not clear |
| Eleanor Spreckley, Kevin Graeme Murph. The L-Cell in Nutritional Sensing and the Regulation of Appetite. Frontiers in nutrition. vol 2. 2015-08-10. PMID:26258126. |
the release of glp-1 has multiple effects, including the secretion of insulin from pancreatic β-cells, decreased gastric emptying, and increased satiation. |
2015-08-10 |
2023-08-13 |
Not clear |
| Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects. Prescrire international. vol 24. issue 160. 2015-08-06. PMID:26034806. |
when they are combined with metformin, two injectable glp-1 analogues, exenatide and liraglutide, have a glucose-lowering potency similar to one or two daily insulin injections. |
2015-08-06 |
2023-08-13 |
human |
| Ofer Yanay, Adam L Bailey, Kelly Kernan, Jerry J Zimmerman, William R Osborn. Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia. Journal of inflammation research. vol 8. 2015-08-05. PMID:26244029. |
glp-1 enhances glucose-stimulated insulin secretion. |
2015-08-05 |
2023-08-13 |
rat |
| Naresh Ramesh, Sima Mortazavi, Suraj Unniappa. Nesfatin-1 stimulates glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide secretion from STC-1 cells in vitro. Biochemical and biophysical research communications. vol 462. issue 2. 2015-08-04. PMID:25930999. |
meal responsive insulin secretion is regulated by incretins glucagon-like peptide-1 (glp-1) and glucose dependent insulinotropic polypeptide (gip). |
2015-08-04 |
2023-08-13 |
mouse |
| Yuichi Makino, Yukihiro Fujita, Masakazu Haned. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. Current opinion in nephrology and hypertension. vol 24. issue 1. 2015-08-03. PMID:25415611. |
the main action of dpp-4 inhibitors is to increase the level of incretin hormones such as glucagon-like peptide-1 (glp-1), thereby stimulating insulin secretion from pancreatic β cells. |
2015-08-03 |
2023-08-13 |
Not clear |